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recessive neurodegenerative disease associated with brain and
liver iron accumulation which typically presents with movement
disorders, retinal degeneration, and diabetes mellitus. Cerulo-
plasmin is a multi-copper ferroxidase that is secreted into plasma
and facilitates cellular iron export and iron binding to transferrin.
Results: A novel homozygous ceruloplasmin gene mutation,
c.2554+1G>T, was identiﬁed as the cause of aceruloplasminemia
in three affected siblings. Two siblings presented with movement
disorders and diabetes. Complementary DNA sequencing showed
that this mutation causes skipping of exon 14 and deletion of
amino acids 809–852 while preserving the open reading frame.
Western blotting of liver extracts and sera of affected patients
showed retention of the abnormal protein in the liver. Acerulo-
plasminemia was associated with severe brain and liver iron
overload, where hepatic mRNA expression of the iron hormone
hepcidin was increased, corresponding to the degree of iron over-
load. Hepatic iron concentration normalized after 3 and 5 months
of iron chelation therapy with deferasirox, which was also asso-
ciated with reduced insulin demands. During short term treat-
ment there was no clinical or imaging evidence for signiﬁcant
effects on brain iron overload.
Conclusions: Aceruloplasminemia can show an incomplete clini-
cal penetrance but is invariably associated with iron accumula-
tion in the liver and in the brain. Iron accumulation inJournal of Hepatology 2
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Introduction
Aceruloplasminemia (ACP) is a rare autosomal recessive disorder
of iron metabolism, where affected patients typically present
with a triad of diabetes mellitus, retinal degeneration, and neuro-
logical symptoms [1]. Absence of ceruloplasmin (CP) in plasma in
combination with mild anemia, hypoferremia, and hyperferritin-
emia is a diagnostic ﬁnding.
The prevalence of ACP is highest in Japan where it is estimated
to be 1 in 2 million [2]. ACP can be caused by nonsense, missense,
splice-site or frame shift mutations in the CP gene, where a total
of about 40 different mutations has been described [3,4]. One ACP
patient, heterozygous for only one missense CP mutation
p.R701W, has been reported suggesting a dominant negative
effect of this mutation [5].
CP ismainly expressed in hepatocytes and glial cells, where the
hepatic splicingvariant includes exons1–19andencodesa soluble,
1040 amino acid protein [6]. Astrocytes express a membrane-
bound glycosylphosphatidylinositol (GPI) anchored form of CP,
resulting from alternative splicing, where a cryptic splice site
within exon 18 is spliced to exon 20 and exon 19 is skipped [6].
Hepatic CP is secreted into the plasma as a glycosylated metallo-
protein that binds >90% of the copper in plasma. CP is a multi-cop-
per ferroxidase which facilitates iron binding to transferrin and
promotes iron export from hepatocytes, macrophages, and glial
cells [7–9]. Iron export frommacrophages is required for the recy-
cling of heme–iron from senescent red blood cells. In contrast, iron
export from hepatocytes supplies iron from stores during iron010 vol. 53 j 1101–1107
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deprivation or iron loss [10]. The only known iron-exporter is fer-
roportin, which is stabilized by GPI-anchored CP in glial cells [9].
How soluble CP in plasma promotes iron export from hepatocytes
remains unknown. Ferroxidase activity and stabilization of ferro-
portin at the plasma-membrane require copper in the active site
of CP [9]. Supply of copper to the hepatocellular Golgi apparatus
for correct CP assembly and folding requires the activities of
ATP7A, which is implicated in intestinal copper uptake, as well
as the activity of ATP7B, which is an intracellular copper transport
protein [11,12]. Menkes disease and Wilson’s disease, which are
associated with genetic defects in ATP7A and ATP7B, respectively,
are characteristically associatedwith lowserumCPconcentrations
resulting from reduced copper supply to the Golgi apparatus [4].
Iron accumulation in ACP affects the liver, pancreas, and cen-
tral nervous system, where the retina, striatum, thalamus, and
dentate nucleus are primarily affected. Brain iron accumulation
can be associated with retinal degeneration, extrapyramidal
symptoms, cerebellar symptoms, and mental dysfunction which
indicate neurodegeneration [3]. In contrast, hepatic iron overload
is not associated with liver disease in ACP but diabetes may be
the result of iron-induced damage of pancreatic islet cells [13].
Disease onset typically occurs in the 4th–5th decade of life and
ACP has a slowly progressive course, with deterioration of neuro-
logical symptoms that can cause typical complications and death
in most patients in the 6th decade of life [3].
Iron chelation therapy with deferoxamine or deferiprone has
been reported to reduce hepatic iron stores in ACP and transfu-
sion of fresh plasma has been shown to partially reconstitute
plasma ferroxidase activity [14–18]. Brain iron concentrations
and neurological symptoms did not improve on iron chelators,
which may be a result of the limited permeability of the blood–
brain barrier for these drugs [14,15].
Herein, we report the clinical presentation of ACP in three sib-
lings and the biochemical consequences of a novel CPmutation in
a canonical splice-site. Further, the clinical, biochemical, and
radiological responses to iron chelation therapy with deferasirox
are presented.
Material and methods
Serum iron parameters, copper, ceruloplasmin, and ferroxidase determination
This study was approved by our local ethics committee and informed consent was
obtained from all patients.
Serum iron parameters, serum copper concentration, serum CP concentra-
tions, and hematological parameters were determined using routine clinical bio-
chemical methods.
Serum ferroxidase activity was determined using p-Phenylenediamine
(Sigma Aldrich, Vienna, Austria) as artiﬁcial substrate according to a previously
published method [19].
CP gene analysis
For cDNA sequencing, total liver RNA extracted from a liver biopsy specimen of
the index case was used as a PCR template after reverse transcription. PCR prod-
ucts were directly sequenced using the BigDye Terminator Kit v.3.2 (Applied Bio-
systems, Vienna, Austria) and an ABI Prism 3130 Genetic Analyzer (Applied
Biosystems, Vienna, Austria). Primers and annealing temperatures for RT-PCR
are listed in Supplementary Table 1.
Exons 11–17 and the exon–intron boundaries of the CP gene were sequenced
from genomic DNA. Primer sequences are listed in Supplementary Table 2.
Sequence analysis was carried out with the Sequencher v4.9 software (Gene-
codes, Ann Arbor, MI) using the Ensemble entries for human CP as reference
(ENSG00000047457, ENST00000264613).1102 Journal of Hepatology 20To screen 100 chromosomes from healthy controls for the presence of an
eventually identiﬁed c.2554+1G>T mutation, a restriction fragment length poly-
morphism assay was set up. The newly identiﬁed c.2554+1G>T mutation creates
an additional RsaI cleavage cut site in the corresponding PCR product, which can
be used for high throughput screening. PCR products were analyzed after RsaI
digestion by HPLC using a WAVE DHPLC system (Transgenomic, Glasgow, UK).
Liver biopsy processing and MRI studies
Sections of formalin-ﬁxed parafﬁn-embedded liver tissue were stained with
hematoxylin and eosin and with Perls’ reagents according to standard methods.
Tissue iron and copper concentrations were determined in an unﬁxed and air-
dried liver biopsy sample by atomic absorption spectroscopy.
For the non-invasive quantiﬁcation of liver iron, T2* relaxation times were
calculated from a fat-saturated multi-echo gradient-echo MR sequence. For the
quantiﬁcation of liver T1-values a fast T1-mapping sequence based on an inver-
sion recovery snapshot FLASH sequence was used which allowed the acquisition
of a single T1 map during one breath hold [20,21]. T1 and T2* acquisitions were
obtained for identical slice positions and slice parameters. T2* and T1 maps were
calculated off-line using ImageJ software (NIH, MD, USA). The parameter maps
were analyzed by the placement of region of interests into different hepatic lobe
segments, whereby identical regions of interests were used in T1 and T2* maps.
Care was taken to avoid the inclusion of large vessels.
Immunoblotting of the liver extracts
Protein extracts from liver biopsies were made by the addition of radio-immuno
precipitation buffer-containing protease inhibitors to a 1 mm3 snap-frozen piece
of liver tissue. After reduction and heat denaturation, protein extracts were sep-
arated on an 8% discontinuous SDS gel. After blotting onto a PVDF membrane, CP
immunoreactivity was detected by incubation of blocked (in 1% skim milk in PBS
containing 0.1% Tween) membranes in goat anti human CP polyclonal antibody
(C0911-Sigma Aldrich, Vienna, Austria) diluted 1:100 in blocking buffer. Immune
complexes were visualized by ECL after incubation of washed membranes in a
rabbit anti goat peroxidase conjugate at a 1:1000 dilution.
Homology modelling
A 3D homology model of truncated CP protein was made based on the PDB tem-
plate 2J5WA using the Swiss-Model workspace [22]. Models were analyzed and
ﬁgures were prepared with Accelrys DS Visualizer v2.0.
Results
Case report
The index case (IV.2) was a 47 year old male who complained of a
progressive gait disorder with falls which had deteriorated over
the last 3–4 years. In the neurological examination the patient
presented with a cerebellar syndrome with a slurred speech, hyp-
ometric saccades, and an intention tremor in the right hand.
When standing he was unsteady with a reduced postural stability
and a pronounced gait ataxia. The patient also had a left-sided
spastic hemiparesis following a traumatic brain injury at the
age of 23 years. Insulin-dependent diabetes mellitus was diag-
nosed at the age of 26 years.
Blood tests showed marked hyperferritinemia and hypoferre-
mia with normal transferrin but decreased transferrin saturation
(Table 1). Serum CP and ferroxidase activity were undetectable.
Serum copper was 2.1 lM (reference range 11–22 lM). No hema-
tological or other biochemical abnormalities were found.
MRI studies and liver histology
To assess tissue iron concentrations, MRI of the abdomen and the
brain with T1 and T2* relaxation time-mapping was carried out.10 vol. 53 j 1101–1107
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Fig. 1. Pedigree of the affected family. Three children of a consanguineous
marriage are affected by ACP, one sibling and the mother are heterozygous
carriers of c.2554+1G>T. The index case is marked by an arrow.
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Fig. 2. Iron accumulation and results from deferasirox treatment. (A) T2 brain
MRI of patient IV.4 shows a marked hypodensity in the area of the basal ganglia
indicating severe iron accumulation (arrows). (B) T2* maps of the brain conﬁrm
the signiﬁcant iron accumulation in the basal ganglia and show iron loading in
the dentate nucleus (red colour indicates areas with a high and dark blue colour
those with a low tissue iron concentration). (C) Abdominal T2* maps of patient
IV.4 show liver iron overload of approximately 250 lmol Fe/g liver tissue before
deferasirox treatment. After 2 months of treatment a reduction in liver iron
concentration was found and no visible liver iron remained after 5 months of
treatment (25 lmol Fe/g liver tissue). (D) Serum ferritin concentrations rapidly
decreased during deferasirox treatment. Arrows indicate the ﬁrst visit after
cessation of iron chelation therapy.
JOURNAL OF HEPATOLOGYAs shown in Fig. 2A, iron accumulation was found in the liver, the
basal ganglia, and the dentate nuclei. Liver histology showed a
normally structured liver with severe hepatocellular iron over-
load but no stainable iron in macrophages (Fig. 3). The results
from hepatic iron quantiﬁcation are shown in Table 1. Based on
these ﬁndings the clinical diagnosis of ACP was made in the pro-
band and family studies were initiated.
Family study
Family studies showed a consanguineous loop and the family his-
tory revealed diabetes in a sister (IV.4) of the proband (Fig. 1). As
shown in Table 1 hyperferritinemia, hypoferremia, and undetect-
able serum CP in two sisters indicated ACP. A movement disorder
with a hypomimia and a postural tremor of both arms were pres-
ent in the older sister (IV.4), whereas all other family members
were clinically unaffected. Ophthalmological investigation in all
individuals showed retinal pigment epithelium changes with a
central depigmentation and a bulls-eye like macula but a normal
vision and perimetry in patients IV.4 and IV.5. MR imaging and
liver histology in the biochemically affected sisters showed iron
accumulation in the basal ganglia, dentate nuclei, and the liver.
The results from family studies further supported the diagnosis
of autosomal recessive inheritance of ACP in this pedigree and
molecular genetic testing was initiated.
Molecular genetics: detection of a CP splice-site mutation
To identify the genetic cause of ACP, hepatic cDNA analysis was
carried out and RT-PCR did not show the expected full length
product but showed an aberrant fragment, 100 bp shorter than
the expected for the PCR product spanning from exons 13 to 16
(Supplementary Fig. 1). Sequencing of the aberrant fragment
showed absence of exon 14 in all biochemically affected family
members. No other mutations were detected.
Direct sequencing of genomic DNA revealed homozygosity for
c.2554+1G>T in intron 14 of the CP gene in all biochemically
affected family members. The mother (III.1) and one unaffected
brother (IV.3) were heterozygous carriers, whereas the other
brother had the wild-type sequence on both alleles. The
c.2554+1G>T mutation of the CP gene was not found in 100 con-
trol chromosomes by PCR ampliﬁcation, restriction fragmentJournal of Hepatology 20length polymorphism, and D-HPLC (Supplementary Fig. 2).
Genetic and biochemical ﬁndings in this family show segregation
of this novel mutation with ACP.
Functional consequences
The c.2554+1G>T mutation, which was shown to cause skipping
of exon 14 is predicted to preserve the open reading frame and10 vol. 53 j 1101–1107 1103
Course on iron chelation treatment
Fig. 3. Liver histology shows a normally structured liver with severe hepa-
tocellular iron over-load. (A) Perls’ stained liver biopsy of the index case with
grade III iron accumulation in hepatocytes and (B) an iron free focus. (C) HE-
stained liver biopsy of the index case showing normally structured liver lobes
without steatosis or inﬂammation but with hemosiderin pigment in hepatocytes.
(D) Reticulin-stained liver biopsy shows minimal ﬁbrosis (grade I). All pictures
were captured using an Olympus BH2 microscope (Olympus, Vienna, Austria)
with a Jenoptik Progress C12 digital camera and Progress Capture Pro 2.5 software
(Jenoptik, Jena, Germany). Panels A and D 100, panels B and C 200.
Research Articleresulted in the loss of 43 amino acids spanning residues G809–
G852 with a molecular weight of 4.6 kDa. This was conﬁrmed
by SDS–PAGE and Western blotting of proteins extracted from
liver biopsies of genetically affected family members and a
healthy control, which showed major immunoreactive bands at
the expected molecular weights (Fig. 4A).
A structural homology model of the mutant protein that
appears to be expressed in the liver of genetically affected indi-
viduals was constructed (Supplementary Fig. 3). Our model sug-
gests that the missing region from G809–G852 is located within
domain 5 (D724–P903) of CP, which contains neither a copper-
binding site nor the ferroxidase site [23]. Analysis of the model
suggests that rearrangement of the termini ﬂanking the deleted
residues would require a cumulative shift in their positions of
approximately 20 Å. The abnormal CP, where the open reading
frame and all copper-binding sites are putatively preserved, is
expressed in hepatocytes, but undetectable in plasma.
Hepcidin in ACP
To study the pathogenesis of iron overload in ACP, mRNA of the
key regulator of iron metabolism hepcidin was quantiﬁed by real
time PCR in liver biopsies. To determine if the observed increase
in hepcidin expression was appropriate for the degree of iron
overload, hepcidin/log (ferritin) ratios were calculated. As shown
in Fig. 4B mean hepcidin mRNA levels and hepcidin/log (ferritin)
ratios are higher in ACP, dysmetabolic siderosis, and patients
with fatty liver disease as compared to patients with C282Y
homozygous hemochromatosis or viral hepatitis.1104 Journal of Hepatology 201To treat iron overload associated with ACP, iron chelation therapy
with deferasirox was started in all three homozygotes for the CP
splice-site mutation with initial doses of 17–20 mg/kg body-
weight per day. Treatment duration ranged from 1 week to
5 months. In the index case deferasirox dose was reduced from
20 to 15 mg/kg/day after 4 weeks due to diarrhea and after
3 months treatment was stopped because of anemia (hemoglobin
9.9 g/dl). Patient IV.4 also developed anemia (hemoglobin 10 g/
dl) and treatment was stopped after 5 months due to a gradual
increase in creatinine up to 1.3 mg/dl. Treatment was discontin-
ued after one week in patient IV.5 because of a skin rash.
Serum ferritin concentrations decreased in all patients
whereas serum iron, transferrin, and transferrin saturation
remained unchanged during deferasirox therapy (Fig. 2D). Non-
invasive iron quantiﬁcation by MRI showed a marked decrease
in liver iron concentration after 3 months in the index case and
in patient IV.4. After 5 months of treatment T1 and T2* relaxation
times in patient IV.4 increased from 390 to 513 ms (normal
570 ± 40 ms) and from 1.8 to 10.9 ms (normal 24 ± 6 ms), respec-
tively. However, there was no imaging evidence for signiﬁcant
effects on brain iron overload during iron chelation therapy in
both patients. Accordingly, neurological symptoms remained sta-
ble during the follow up. Both patients reported a transient
reduction in their insulin demands on deferasirox. Iron chelation
therapy with deferasirox is effective in reducing hepatic iron con-
centrations and improves endogenous insulin production, but has
no short term effect on brain iron accumulation.
Discussion
CP is a multi-copper ferroxidase essential for iron homeostasis
which facilitates cellular iron efﬂux [7,24]. Lack of functional CP
is typically associated with iron overload in the liver, pancreas,
and the basal ganglia as illustrated in the reported cases. Retinal
degeneration has a penetrance ranging from 75% to 93% in
patients with ACP and retinal pigment epithelium changes were
present in patients IV.4 and IV.5 [4]. It is unclear if the incomplete
penetrance of neurological symptoms and diabetes in our
patients is a result of disease modiﬁers or reﬂects the natural
course of ACP. Both clinically affected siblings are diabetic since
their twenties, whereas the youngest genetically affected sibling
is asymptomatic and not diabetic at the age of 37, which suggests
the presence of modiﬁers that affect disease expression.
In agreement with previous reports of ACP, none of the genet-
ically affected individuals had evidence of impaired biochemical
liver function or advanced ﬁbrosis despite the signiﬁcant hepato-
cellular iron overload that exceeded the thresholds for hepatic
ﬁbrosis established in hemochromatosis cohorts [13,25,26]. This
observation suggests that iron is only a cofactor in hepatic ﬁbro-
genesis [27].
Liver histology showed the presence of iron in hepatocytes,
whereas no iron was found in macrophages. Moreover, magnetic
resonance imaging also showed the absence of iron overload in
the spleen, suggesting that iron overload in Kupffer cell is a late
event in ACP [15]. This observation suggests that CP is important
for hepatocellular iron efﬂux, whereas CP-independent mecha-
nisms for iron export from macrophages exist. If CP was indis-
pensable for iron export from recycling macrophages, one0 vol. 53 j 1101–1107
Table 1. Demographic, hematological, serum iron parameters, hepatic, and genetic data of members of the affected family at the time of ﬁrst presentation.
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CP - genotype
Abbreviations: f, female; m, male; Hb, hemoglobin; TfS, transferrin saturation; SC, serum ceruloplasmin; HC, hepatic copper concentration; HIC, hepatic iron concentration;
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Fig. 4. Proteins extracted from liver biopsies of genetically affected family
members. (A) Western blotting of protein extracts from a control liver shows an
immunoreactive band at 150 kDa. In protein extracts from liver biopsies of
genetically affected family members the strongest signal has an apparent
molecular weight of 145 kDa and is slightly lower than the major band in the
control liver extract. The difference corresponds to the predicted loss of 4.6 kDa in
molecular weight of the protein translated from the abnormal transcript in
c.2554+1G>T homozygotes. (B) Hepcidin mRNA concentrations in liver biopsies of
the three ACP patients are comparable to those in patients with non alcoholic
fatty liver disease (NAFLD) or dysmetabolic siderosis (DMS) but higher than in
patients with HFE hemochromatosis (HFE HH) or viral hepatitis.
JOURNAL OF HEPATOLOGYwould expect more pronounced anemia and even higher sTfR
concentrations.
In our ACP patients, stainable iron was restricted to hepato-
cytes, in comparison to patients with advanced hemochromatosis
or transfusional iron overload where the iron storage typically
affects parenchymal cells and macrophages. The decline of serum
ferritin on deferasirox treatment in ACP patients was faster than
in patients with ß-thalassemia, which suggests that iron-loaded
hepatocytes are the main source of serum ferritin and hepatocel-
lular iron is more accessible to deferasirox than macrophageal
iron. The prompt increase in serum ferritin after cessation of def-
erasirox treatment may indicate a redistribution of iron, since the
re-accumulation of food iron in such a short time appears
unlikely.
Hepatocellular iron overload induces expression of the pep-
tide hormone hepcidin in normal individuals, which causes ferro-
portin degradation. This results in cellular iron retention and
reduced iron absorption [28,29]. The observation that hepatic
hepcidin mRNA expression in ACP patients and in dysmetabolic
siderosis patients are comparable, but low in HFE hereditary
hemochromatosis, suggests that CP but not HFE is dispensable
for iron-mediated hepcidin regulation [30]. We found higher hep-
cidin mRNA expression in ACP than in viral hepatitis patients
where hepcidin expression is suppressed [31], which also sug-
gests that hepcidin responds normally to iron in ACP. Normal
hepcidin regulation in ACP supports the concept that regional
iron accumulation in affected organs results from disturbed cellu-
lar iron metabolism rather than from alterations in total body
iron homeostasis.
The functional consequence of the splice-site mutation
c.2554+1G>T is the skipping of exon 14, which preserves the
open reading frame. The structural model suggests that the
abnormal protein folds into a potentially functional protein, but
such a signiﬁcant structural change within domain 5 of CP is
likely to affect the stability of the variant protein, resulting in
intracellular retention. The phenotypic similarity with CP non-
sense mutations further suggests that this variant is dysfunc-
tional [32].
Skipping of exon 14 is also predicted to affect the alternative
transcript in the brain, where activation of a cryptic splice-site
results in direct splicing of exons 18–20 [6]. Iron accumulation
in the basal ganglia of c.2554+1G>T homozygotes suggests the
absence of functional GPI-anchored CP and supports the impor-
tance of correct protein folding for the activity and stability of
GPI-anchored CP. Ferroxidase activity is required to stabilize
the iron export pump ferroportin in cells expressing GPI-
anchored CP, which provides a molecular explanation for cellular
iron retention in ACP [9].Journal of Hepatology 20Iron-mediated lipid peroxidation and oxidative stress are the
main causes of neurodegeneration secondary to brain iron accu-
mulation [33,34]. To reduce iron toxicity chelation therapy was
introduced in ACP. The iron chelator deferoxamine was effective
in reducing hepatic iron overload and leading to a partial
improvement of neurological symptoms and brain iron accumu-
lation, as reported in a single case report [16]. The positive effect
of deferoxamine on central nervous symptoms and signs was not10 vol. 53 j 1101–1107 1105
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found in subsequent studies [14,15], which highlights the low
permeability of the blood–brain barrier for deferoxamine. Despite
the lower molecular weight and more lipophilic properties of def-
eriprone, this orally bioavailable iron chelator had no beneﬁcial
effect in ACP in a previous report [14]. In agreement, we found
no improvement of neurological symptoms or brain iron accumu-
lation during deferasirox treatment over a period of several
months. Deferasirox could still be an effective brain iron chelator,
whose clinical beneﬁt might be missed after a short term treat-
ment. By comparison, the neurological improvement on zinc-sul-
phate was found after 15 months of treatment in a patient with
ACP [35]. In contrast, hepatic iron concentration and insulin
requirements improved in both patients who were treated for 3
and 5 months, respectively. Taken together, short term deferasi-
rox is effective in reducing hepatic iron overload, but ineffective
for the treatment of brain iron accumulation. In all patients, side
effects prohibited the long term therapy that may be required to
mobilize iron from the brain. Given the high efﬁcacy of a high
dose of deferasirox, a low dose of the iron chelator may have a
more favourable side effect proﬁle, which in turn may allow for
a long term and combination therapy. Recent studies in an animal
model of Friedreich’s ataxia suggest that the combined use of
pyridoxal isonicotinoyl hydrazone and deferoxamine is an effec-
tive treatment of iron accumulation in glial cells [36]. Further
work is required to determine if similar strategies can be devel-
oped for patients with ACP and other neurodegenerative diseases
that are associated with brain iron accumulation.
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